#United States #Anixa Biosciences #San Jose #CAR-T therapy #liraltagene

Anixa Biosciences Achieves a Major Milestone in Cancer Treatment

Anixa Biosciences, Inc., a pioneer in biotechnological solutions for cancer treatment, has reached a significant milestone with the United States Adopted Names (USAN) Council’s approval of the non-proprietary name for its innovative CAR-T therapy. This therapy, designed specifically for the treatment of recurrent ovarian cancer, is now officially recognized under the name 'liraltagene autoleucel.' This development not only follows a similar earlier recognition by the World Health Organization's International Nonproprietary Names (INN) Expert Committee but also serves as a crucial step towards the therapy's commercialization and broader acceptance in the medical community.

The approval of 'liraltagene autoleucel' symbolizes more than just a name; it represents a significant leap forward in Anixa’s mission to combat cancer effectively. Dr. Amit Kumar, Chairman and CEO of Anixa, emphasized that securing this name facilitates the establishment of a universally acknowledged and conflict-free designation for their CAR-T therapy globally. This achievement opens the door for clearer communication regarding treatment options, ultimately benefiting patients seeking effective therapies.

The CAR-T therapeutic approach employs the novel follicle stimulating hormone receptor (FSHR)-targeted technology to attack cancer cells associated with ovarian cancer. This is particularly exciting, as FSHR is found on normal ovarian cells as well as on the tumor vasculature. Notably, this new type of therapy, referred to as chimeric endocrine receptor-T cell (CER-T) technology, utilizes a natural ligand rather than traditional antibody fragments, paving a unique pathway within the CAR-T landscape.

Currently, lira-cel is under investigation in a Phase 1 clinical trial aimed at evaluating its safety and efficacy in patients with recurrent ovarian cancer who have failed previous treatments. The trial is being conducted in partnership with the esteemed Moffitt Cancer Center, noted for its groundbreaking work in cancer immunotherapy.

The establishment of a non-proprietary name also aids in the safe prescription and dispensing of medications, a responsibility that the USAN Council takes seriously. Co-sponsored by prestigious medical organizations, the Council’s mandate emphasizes the importance of maintaining high standards in medication naming to ensure safety and consistency for patients and healthcare providers.

Anixa's innovative approach does not stop at CAR-T therapies. The company is committed to various fronts in cancer treatment, partnering with leading research institutions, such as the Cleveland Clinic, to further develop vaccine technologies aimed at breast and ovarian cancers, among others. This strategy ensures that Anixa remains at the forefront of cancer therapeutics, continually exploring emerging technologies to improve treatment accessibility and outcomes.

As Anixa progresses with the clinical trials of liraltagene autoleucel, it is clear that this company is not just contributing to cancer treatment but is poised to change how we approach it altogether. With 'liraltagene autoleucel' now recognized, the potential for future therapeutic innovations and real-world applications is brighter than ever, inspiring hope in patients and healthcare professionals alike.

For further information about Anixa Biosciences and its innovative solutions, please visit their official website.